Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
PaperCitations, authors & open-access status
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 877 citations, 2017 year and green oa status.
877
Citations
2017
Year
green
OA Status